We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02247726
Recruitment Status : Completed
First Posted : September 25, 2014
Last Update Posted : May 27, 2022
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to evaluate the safety and immunogenicity of an RSV-F protein nanoparticle vaccine, with aluminum, in healthy third-trimester pregnant women and to assess the impact of maternal immunization on infant safety through one year of life.

Condition or disease Intervention/treatment Phase
Respiratory Syncytial Virus Infections Drug: Saline Placebo (0.5mL injection) Drug: RSV F vaccine (0.5mL injection) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase II Randomized, Observer-Blind, Placebo-Controlled, Study to Evaluate the Safety and Immunogenicity of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum, in Healthy Third-trimester Pregnant Women and to Assess the Impact of Maternal Immunization on Infant Safety Through One Year of Life
Study Start Date : September 2014
Actual Primary Completion Date : July 2016
Actual Study Completion Date : July 2016

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: Treatment Group A
Saline Placebo (0.5mL injection)
Drug: Saline Placebo (0.5mL injection)
Other Name: 0.9% Sodium Choloride

Experimental: Treatment Group B
RSV F vaccine with adjuvant (0.5mL injection)
Drug: RSV F vaccine (0.5mL injection)
Other Name: RSV F Protein with Aluminum adjuvant

Primary Outcome Measures :
  1. Counts and percentage of subjects with solicited injection site and systemic reactogenicity within seven days of vaccination. [ Time Frame: Day 0 to Day D+180 ]
    In Maternal Subjects

  2. Counts and percentage of subjects with unsolicited (local and systemic) adverse events (AE), unscheduled medically-attended adverse events (MAEs), and serious adverse events (SAEs) through delivery and six (6) months thereafter. [ Time Frame: Day 0 to Day D+180 ]
    In Maternal Subjects

  3. Clinical safety laboratory assessments of select serum chemistry and hematology parameters through delivery. [ Time Frame: Screening to Day 14 ]
    In Maternal Subjects

  4. Counts and percentage of subjects with post-immunization onset of specific complications of third-trimester pregnancy and delivery [ Time Frame: Day 0 to Day 28 - 42 ]
    In Maternal Subjects

  5. Counts and percentage of term healthy infants appropriate for gestational age. [ Time Frame: Day 28 - 42 ]
    In Infant subjects

  6. Neonatal SAEs (including congenital anomalies, respiratory failure, fever/infection, and neonatal death or other adverse events/complications that necessitate extended hospitalization). [ Time Frame: Birth to Day 365 ]
    In Infant Subjects

  7. Growth and development over one year [ Time Frame: Birth to Day Day 365 ]
    In Infant Subjects

  8. Counts and proportion of infants with unsolicited adverse events [ Time Frame: Birth to Day 365 ]
    In Infant Subjects

  9. Counts and proportions of infants with medically-attended RSV lower respiratory tract infection (LRTI), and age of onset of those infections. [ Time Frame: Birth to Day 365 ]
    In Infant Subjects

Secondary Outcome Measures :
  1. Immunogenicity as assessed by serum IgG antibody titers specific fro the F-Protein antigen. [ Time Frame: Birth to Day 180 ]
    In Infant Subjects

  2. Serum antibody titers inhibiting binding of labeled palivizumab to RSV F protein. [ Time Frame: Birth to Day 180 ]
    In Infant Subjects

  3. Serum microneutralization (MN) titers against RSV/A and B.previously referenced, but based on GMT. [ Time Frame: Birth to Day 180 ]
    In Infant Subjects

Other Outcome Measures:
  1. Counts and proportions of maternal subjects with RSV-related respiratory illness as detected by active and passive surveillance. [ Time Frame: Day 0 to Day 180 ]
    In Maternal Subjects

  2. Counts and proportions of infants with non-medically attended RSV-related respiratory illness as detected by active and passive surveillance. [ Time Frame: Birth to Day 365 ]
    In Infant Subjects

  3. Counts and proportions of infants with medically attended, non-RSV LRTI as assessed by multiplex real time (RT)-PCR. [ Time Frame: Birth to Day 365 ]
    In Infant Subjects

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

Pregnant women must meet all of the following criteria to be eligible to participate:

  1. ≥18 and ≤40 years-of-age.
  2. Singleton pregnancy of 33 to 35 weeks gestation on the day of planned vaccination.
  3. Good general maternal health as demonstrated by:

    • Medical history (including history of adverse reactions to prior vaccines and allergies).
    • Physical examination including at least vital signs (blood pressure, pulse, respirations, and oral temperature); weight; height; examination of the HEENT, cardiovascular, pulmonary, gastrointestinal (abdominal), musculoskeletal, lymphatic, and dermatologic organ systems; and documentation of fetal heart tones.
    • Clinical laboratory parameters including normal blood urea nitrogen, creatinine, ALT, AST, total bilirubin, alkaline phosphatase (ALP), hemoglobin, white blood count, and platelet count; and serologic exclusion of infection with hepatitis B (HBV) and C (HCV) viruses and HIV (as required). Note that normal ranges for vital signs and clinical laboratory parameters will be based on third trimester values published in Sheffield et al. [2013] and/or reference ranges for the third trimester of pregnancy of the central laboratory.
  4. Documentation that fulfills one of the following:

    • Detailed (level II) second trimester or later anatomic ultrasound with no significant anatomic or growth abnormalities identified; OR
    • Routine second trimester or later ultrasound with no significant anatomic or growth abnormalities identified, PLUS at least one of the following:

      • Normal first trimester screening (based on ultrasound + serum analytes); or
      • Normal cell-free fetal DNA; or
      • Normal chorionic villus sampling (CVS) or amniocentesis; or
      • Normal second trimester maternal serum quadruple screen; or
      • Normal first and second trimester screening using integrated, sequential, or contingency approach; or
      • Abnormal first or second trimester screening followed by normal CVS, amniocentesis, or cell-free fetal DNA.
  5. Able to understand, and both willing and physically able to comply with study procedures. This includes anticipation of reasonable geographic proximity to the study clinic and adequate transportation to comply with scheduled and unscheduled study follow-up visits.
  6. Able and willing to provide written informed consent for themselves and infant.

Exclusion Criteria:

Pregnant women will be excluded if there is historical, physical examination, or laboratory evidence of any of the following criteria:

  1. Symptomatic cardiac or pulmonary disease requiring chronic drug therapy, including hypertension and asthma. Asthma will be exclusionary if the subject is receiving chronic systemic glucocorticoids at any dose or inhaled glucocorticoids at any dose >500µg per day of beclamethasone or fluticasone, or >800μg per day of budesonide.
  2. Pre-pregnancy body mass index (BMI) of ≥35 or <18.5.
  3. Hemoglobinopathy (including known sickle trait or thalassemias, even if asymptomatic) or blood dyscrasias.
  4. Hepatic or renal dysfunction.
  5. Established diagnosis of seizure disorder, regardless of therapy.
  6. Auto-immune disease or known immunodeficiency syndrome.
  7. Endocrine disorders, including (but not limited to) hyperthyroidism, untreated hypothyroidism, and glucose intolerance (e.g., diabetes mellitus type 1 or 2) antedating pregnancy, or occurring during pregnancy and requiring interventions other than diet for control.
  8. History of major gynecologic or major abdominal surgery, including bariatric surgery.
  9. Known HIV, HBV, or HCV infection, as assessed by serologic tests conducted during the current pregnancy or as a procedure during the screening period of the study.
  10. Primary genital herpes simplex (HSV) infection during the current pregnancy.
  11. Current alcohol or drug abuse.
  12. Documentation that current pregnancy results from fertility treatments, rape, or incest.
  13. Documentation that the infant will be a ward of the state or be released for adoption.
  14. Neuro-psychiatric illness deemed likely to interfere with protocol compliance, safety reporting, or receipt of pre-natal care; or requiring treatment with psychotropic drugs.
  15. History/presence of deep venous thrombosis or thromboembolism, or the use of anticoagulants during pregnancy.
  16. Untreated red blood cell allo-immunization.
  17. Prior stillbirth or neonatal death, or multiple (≥3) spontaneous abortions.
  18. Prior preterm delivery ≤34 weeks gestation or having ongoing intervention (medical/surgical) in current pregnancy to prevent preterm birth.
  19. Greater than five (5) prior deliveries.
  20. Previous infant with a known genetic disorder or major congenital anomaly.
  21. Receipt of investigational drugs or immune globulins (with the exception of prophylactic anti-Rho D immune globulin) within six (6) months prior to the administration of the study vaccine.
  22. Chronic administration (defined as more than 14 continuous days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of the study vaccine. An immunosuppressant dose of glucocorticoid will be defined as a systemic dose ≥10mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids will be permitted except for the limit established in exclusion criterion #1.
  23. Any other physical, psychiatric or social condition which may, in the investigator's opinion, increase the risks of study participation to the maternal subject or the fetus/infant; or may lead to the collection of incomplete or inaccurate safety data.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02247726

Layout table for location information
United States, Idaho
Advanced Specialty Research
Nampa, Idaho, United States, 83687
United States, Kansas
Hutchinson Clinic, P.A.
Hutchinson, Kansas, United States, 67502
University of Kansas Medical Center Research Institute
Kansas City, Kansas, United States, 66160
United States, Nebraska
Meridian Clinical Research
Norfolk, Nebraska, United States, 68701
United States, North Carolina
Duke University
Durham, North Carolina, United States, 27705
United States, Pennsylvania
Magee- Womens Hospital of UPMC
Pittsburgh, Pennsylvania, United States, 15213
United States, Texas
Baylor College of Medicine
Houston, Texas, United States, 77030
Sponsors and Collaborators
Layout table for investigator information
Study Director: Clinical Development Novavax, Inc.
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Novavax
ClinicalTrials.gov Identifier: NCT02247726    
Other Study ID Numbers: RSV-M-203
First Posted: September 25, 2014    Key Record Dates
Last Update Posted: May 27, 2022
Last Verified: May 2022
Keywords provided by Novavax:
Third Trimester
Maternal Immunization
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiratory Syncytial Virus Infections
Virus Diseases
Pneumovirus Infections
Paramyxoviridae Infections
Mononegavirales Infections
RNA Virus Infections